doi.bio unifies AI-powered literature synthesis with interactive molecular context. Structural biologists cut onboarding time in half and make structurally-aware decisions with confidence.
R&D lives in two places—papers and proteins—but today's tools don't connect them
PDFs, notes, and wikis rarely converge into reusable institutional memory. Scientists spend hours re-synthesizing context.
Molecular viewers exist in isolation, forcing scientists to context-switch between literature insights and 3D analysis.
Scripts and pipelines run without capturing reasoning, creating compliance headaches and repeated mistakes.
doi.bio blends AI literature synthesis, interactive molecular context, and guided workflows into a single collaborative surface.
AI extracts targets, ligands, and assays from papers—building an interlinked graph that stays synced with 3D structures.
PDB and AlphaFold structures load instantly, with pocket annotation, clash detection, and conservation analysis built in.
Trigger docking, MD, or custom compute with one click—results flow back into the narrative with full provenance.
Decisions, rationales, and experiments become shared IP. New scientists inherit the full context in hours, not weeks.
AI-enabled discovery is accelerating, and structural biology is at the center
Structural biologists, computational chemists, medicinal chemists in pharma, biotech, CROs, and academic labs
Days → hours for target triage. 50%+ faster onboarding. Fewer dead-end designs through early structural alerts.
AlphaFold opened the floodgates. Teams need tools to operationalize 200M+ predictions—not just view them.
Structural biochemist with ML PhD and decades of Linux/software experience. Deep expertise in PDB/AlphaFold ecosystems, molecular visualization, and AI-assisted research tools.
Assembling leaders across medicinal chemistry, platform engineering, business development, and regulatory strategy to accelerate delivery and market fit.
Partner with us during rollout. Design-partner spots are limited.